Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Orchid BioSciences (Princeton, NJ) announced the acquisition of Cellmark Diagnostics from AstraZeneca on financial terms that were not disclosed; CEO Dale…
Cellmark traces a continuous lineage from ICI (1987) through Zeneca, AstraZeneca, Orchid, LabCorp, a 2018 management buyout, and ultimately Eurofins (August…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Carve-out of AZ's UK forensic/genetic-identity diagnostics business. Financial terms were not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Orchid BioSciences Inc. / AstraZeneca (Cellmark Diagnostics unit) (this deal) | 2001 | — | — |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals